- Bio Protocol funds $80K brain health trial, earning CLAW royalty tokens.
- Staked BIO tokens rise to 125M, tightening supply and boosting demand.
- Harmonic chart pattern signals a possible BIO price rally toward $0.1787.
The Bio Protocol (BIO) token has regained strong momentum after a sharp pullback earlier this month, climbing to a six-month high of $0.1514 before settling near $0.138.
The recovery follows a string of bullish catalysts, ranging from real-world biotech partnerships to a surge in staking activity, while traders are now watching technical signals that hint at further upside.
BIO price recovery sparks fresh momentum
After dropping to $0.0962 during the recent correction, BIO has staged an impressive rebound of more than 50% in a matter of days.
The strong recovery comes at a time when the broader crypto market has been under selling pressure, yet Bio Protocol has managed to move against the trend.
At press time, the token was trading nearly 100% higher on the month, underscoring its growing resilience.
Trading activity has also intensified. Daily volumes have spiked by more than 700% last week, crossing $440 million as new investors piled in.
This sharp increase in liquidity has strengthened confidence that BIO’s market depth is improving, making it more attractive for both retail and institutional traders.
Clinical trial funding lifts sentiment
One of the strongest drivers of BIO’s price rally has been the announcement of its first major biotech initiative.
Through its partner Cerebrum DAO, the Bio Protocol community approved $80,000 in funding for a Phase 2 human clinical trial of Percepta, a supplement targeting memory loss and neurodegeneration.
Big week in the Biosphere 🧪
• Launched Bio Markets w/ real-time DeSci analytics & BioAgent trading coming
• 125M+ $BIO staked + 1M BioXP Boost
• Funding human trial for Percepta $CLAW
• Molecule V2 DeSci equity
• $BeeARD psilocybin derivativeRead the full weekly update: https://t.co/l5lH2Utcjo
— Bio Protocol (@BioProtocol) August 17, 2025
The deal not only gives Bio Protocol direct exposure to real-world biotech outcomes but also provides it with CLAW tokens.
These tokens are tied to royalties from Percepta sales, creating a potential…